

# Journal Pre-proof

Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease

Salvatore Petta, Giada Sebastiani, Mauro Viganò, Javier Ampuero, Vincent Wai-Sun Wong, Jerome Boursier, Annalisa Berzigotti, Elisabetta Bugianesi, Anna Ludovica Fracanzani, Calogero Cammà, Marco Enea, Marraud des Grottes, Vito Di Marco, Ramy Younes, Aline Keyrouz, Sergio Mazzola, Yuly Mendoza, Grazia Pennisi, Manuel Romero-Gomez, Antonio Craxi, Victor de Ledinghen

PII: S1542-3565(20)30908-3  
DOI: <https://doi.org/10.1016/j.cgh.2020.06.045>  
Reference: YJCGH 57319

To appear in: *Clinical Gastroenterology and Hepatology*  
Accepted Date: 17 June 2020

Please cite this article as: Petta S, Sebastiani G, Viganò M, Ampuero J, Wai-Sun Wong V, Boursier J, Berzigotti A, Bugianesi E, Fracanzani AL, Cammà C, Enea M, Grottes Md, Di Marco V, Younes R, Keyrouz A, Mazzola S, Mendoza Y, Pennisi G, Romero-Gomez M, Craxi A, de Ledinghen V, Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease, *Clinical Gastroenterology and Hepatology* (2020), doi: <https://doi.org/10.1016/j.cgh.2020.06.045>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 by the AGA Institute



**TITLE: Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease**

**AUTHORS:** Salvatore Petta<sup>1</sup>, Giada Sebastiani<sup>2</sup>, Mauro Viganò<sup>3</sup>, Javier Ampuero<sup>4</sup>, Vincent Wai-Sun Wong<sup>5</sup>, Jerome Boursier<sup>6</sup>, Annalisa Berzigotti<sup>7</sup>, Elisabetta Bugianesi<sup>8</sup>, Anna Ludovica Fracanzani<sup>9</sup>, Calogero Cammà<sup>1</sup>, Marco Enea<sup>10</sup>, Marraud des Grottes<sup>11</sup>, Vito Di Marco<sup>1</sup>, Ramy Younes<sup>8</sup>, Aline Keyrouz<sup>2</sup>, Sergio Mazzola<sup>12</sup>, Yuly Mendoza<sup>7</sup>, Grazia Pennisi<sup>1</sup>, Manuel Romero-Gomez<sup>4</sup>, Antonio Craxì<sup>1</sup>, Victor de Ledinghen<sup>11</sup>.

**INSTITUTIONS:**

<sup>1</sup>Sezione di Gastroenterologia e Epatologia, PROMISE, Università di Palermo, Italia

<sup>2</sup>Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal QC, Canada

<sup>3</sup> Hepatology Unit, Ospedale San Giuseppe, University of Milan, Milan, Italy.

<sup>4</sup> Digestive Diseases Unit. Hospital Universitario Virgen del Rocío and ciberEHD, Instituto de Biomedicina de Sevilla, University of Seville, Sevilla, Spain.

<sup>5</sup>Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong

<sup>6</sup> Hepato-Gastroenterology Department, Angers University Hospital, Angers, France.

<sup>7</sup> Hepatology, University Clinic for Visceral Surgery and Medicine, Inselspital, DMBR, University of Bern, Switzerland

<sup>8</sup> Division of Gastroenterology, Department of Medical Sciences, University of Torino, Torino, Italy

<sup>9</sup> Department of Pathophysiology and Transplantation, Ca' Granda IRCCS Foundation, Policlinico Hospital, University of Milan, Italy

<sup>10</sup> Dipartimento di Scienze Economiche, Aziendali e Statistiche, University of Palermo, Palermo, Italy.

<sup>11</sup> Centre d'Investigation de la Fibrose Hépatique, INSERM U1053, Hôpital Haut-Lévêque, Bordeaux University Hospital, Pessac, France

<sup>12</sup> Clinical Epidemiology and Cancer Registry Operative Unit, University Hospital Policlinico "Paolo Giaccone", Palermo, Italy.

**CORRESPONDING AUTHOR:** Dr. Salvatore Petta, Section of Gastroenterology and Hepatology, PROMISE, Policlinico Universitario Paolo Giaccone, Piazza delle Cliniche, 2, 90127 Palermo, Italy. Phone: +39 091 6552170. Fax +39 091 655 2156. E-mail: salvatore.petta@unipa.it.

**NUMBER OF FIGURES/SUPPLEMENTAL figures: 4/1**

**NUMBER OF TABLES/SUPPLEMENTAL TABLES: 2/2**

**LIST OF ABBREVIATIONS:** NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; LSM: liver stiffness measurement; HCC: hepatocellular carcinoma.

**CONFLICT OF INTEREST:** SP has acted as speaker and/or advisor for Abbvie, Gilead and Intercept. GS has acted as speaker for Merck, Gilead, Abbvie, Novonordisk, served as an advisory board member for Merck, Gilead, Intercept and Novartis and has received unrestricted research funding from Merck and Theratec. GS is supported by a Junior 1 and 2 Salary Award from Fonds de Recherche Santé du Québec (FRQS) (#27127 and #267806) and research salary from the Department of Medicine of McGill University.

**Author contributions:** S Petta, G Sebastiani, M Viganò, J. Ampuero, M Romero-Gomez, VW Wong, J Boursier, A Berzigotti, E Bugianesi, AL Fracanzani, C Cammà, M des Grottes, V Di Marco, M Younes, A Keyrouz, S Mazzola, Y Mendoza, G Pennisi, A Craxì,

V de Ledinghen had full control of the study design, data analysis and interpretation, and preparation of article. All authors were involved in planning the analysis and drafting the article. The final draft article was approved by all the authors.

### **Abstract:**

**Background & Aims:** Patients with advanced fibrosis related to nonalcoholic fatty liver disease (NAFLD) are at risk of developing hepatic and extrahepatic complications. We investigated whether, in a large cohort of patients with NAFLD and compensated advanced chronic liver disease, baseline liver stiffness measurements (LSMs) and their changes can be used to identify patients at risk for liver-related and extrahepatic events.

**Methods:** We performed a retrospective analysis of consecutive patients with NAFLD (n=1039) with a histologic diagnosis of F3–F4 fibrosis and/or LSMs>10 KPa, followed for at least 6 months, from medical centers in 6 countries. LSMs were made by FibroScan using the M or XL probe and recorded at baseline and within 1 year from the last follow-up examination. Differences between follow up and baseline LSMs were categorized as: improvement (reduction of more than 20%), stable (reduction of 20% to an increase of 20%), impairment (an increase of 20% or more). We recorded hepatic events (such as liver decompensation, ascites, encephalopathy, variceal bleeding, jaundice, or hepatocellular carcinoma [HCC]) and overall and liver-related mortality during a median follow-up time of 35 months (interquartile range, 19–63 months).

**Results:** Based on Cox regression analysis, baseline LSM was independently associated with occurrence of hepatic decompensation (hazard ratio [HR], 1.03; 95% CI, 1.02–1.04; P<.001), HCC (HR, 1.03; 95% CI, 1.00–1.04; P=.003), and liver-related death (HR, 1.02; 95% CI, 1.02–1.03; P=.005). In 533 patients with available LSMs during the follow-up period, change in LSM was independently associated with hepatic decompensation (HR, 1.56; 95% CI, 1.05–2.51; P=.04), HCC (HR, 1.72; 95% CI, 1.01–3.02; P=.04), overall mortality (HR, 1.73; 95% CI, 1.11–2.69; P=.01), and liver-related mortality (HR, 1.96; 95% CI, 1.10–3.38; P=.02).

**Conclusions:** In patients with NAFLD and compensated advanced chronic liver disease, baseline LSM and change in LSM are associated with risk of liver-related events and mortality.

**KEY WORDS:** NASH, steatohepatitis, cACLD, prognostic factor

### **Need to Know**

Background: It is not clear whether, in patients with nonalcoholic fatty liver disease (NAFLD) and compensated advanced chronic liver disease, baseline liver stiffness measurements (LSMs) or their changes can be used to identify patients at risk for liver-related and extrahepatic events.

Findings: In patients with NAFLD and compensated advanced chronic liver disease, baseline LSM and change in LSM are associated with risk of liver-related events and mortality.

Implications for patient care: LSMs should be made at multiple timepoints in patients with NAFLD and compensated cirrhosis to monitor disease progression.

## Introduction

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide with a prevalence of about 25% in general population [1,2]. The clinical relevance of NAFLD arises from the increased risk of developing both liver-related and extrahepatic complications [3-5].

Recent long-term natural history studies and a meta-analysis pooling available evidence demonstrated that the severity of liver fibrosis and especially the presence of advanced fibrosis -defined as stage F3 or F4 fibrosis- is the main driver of prognosis in NAFLD, being the main risk factor for developing not only liver-related events but also extrahepatic complications [6-8]. Along this line, noninvasive markers that can predict liver disease severity and outcomes in patients with NAFLD and advanced fibrosis are a major unmet need.

Liver stiffness measurement by FibroScan® is a noninvasive and widely available tool with validated diagnostic accuracy for advanced fibrosis in patients with NAFLD [9], and also used identifying patients at low risk for esophageal varices saving endoscopic screening [10], and lastly, increase over time of LSM predicted liver-related events in patients with chronic hepatic C [11].

Data about the accuracy of LSM in the prediction of events in NAFLD, and especially in patients with NAFLD and F3-F4 fibrosis, are scarce. With this in mind, we investigated whether, in a large cohort of patients with NAFLD and compensated advanced chronic liver disease (cACLD), LSM at baseline and its changes during follow-up, are accurate for the prediction of liver-related and extrahepatic events.

## **Patients and Methods**

### ***Patient Selection***

Data from 1,039 patients and prospectively recruited at the first diagnosis of NAFLD with cACLD in 10 centers were retrospectively reviewed and analyzed. Inclusion and exclusion criteria were reported in supplemental material.

The study was carried out in accordance with the principles of the Helsinki Declaration, and with local and national laws. Approval was obtained from the hospital Internal Review Boards and their Ethics Committees, and written informed consent for the study was obtained from all patients.

### ***Patient Evaluation (more data available in Supplemental material)***

Clinical, anthropometric, biochemical and histological data were collected at the time of enrollment.

Follow-up visits, laboratory tests, ultrasound examination, esophageal gastroscopy, and management of both esophageal varices and HCC were performed as for guidelines [12-14].

During follow-up, liver-related and extrahepatic events were recorded. Liver-related events were categorized as either liver decompensation (occurrence of ascites and/or bleeding varices and/or encephalopathy and/or jaundice) or development of HCC. They were also evaluated for liver transplantation, as were patients who experienced LD, when indicated [14]. Extrahepatic events were categorized as either cardiovascular events (stroke, transient ischaemic attack, myocardial infarction, unstable angina) or extrahepatic

cancers. Evidence of extrahepatic events was provided by clinical charts from emergency areas and/or hospitalization. Death was also recorded and classified according to associated events (liver-related, including liver transplantation, or unrelated).

Transient elastography was performed with the FibroScan (Echosens, Paris, France) medical device, using the M or XL probes. In each center [15]. LSM was recoded within 3 months from blood tests and within 1 year from the last follow-up.

***Statistics (more data available in Supplemental material)***

To evaluate the occurrence of liver decompensation, HCC, cardiovascular events, extrahepatic cancers, and death, we included all consecutive patients who had at least 6 months of follow-up. Patients lost at follow-up (12% of the total population) were censored at the time of the last visit.

Continuous variables were summarized as mean  $\pm$  standard deviation, and categorical variables as frequency and percentage. Delta LSM was defined as the difference between follow-up and baseline LSM and was categorized as  $<-20\%$  (improvement),  $-20\%$  to  $+20\%$  (stable), and  $>+20\%$  (impairment). This last criterion was used because values above and below 15% were considered as a normal variability of the procedure (as defined per the interquartile to median ratio of 30%). Covariates used for the multivariate model Cox were chosen based on their significance in univariate analysis ( $p<0.10$ ). Variables in the final model with a P value of  $<0.05$  were considered statistically significant. In order to take into account the between-center heterogeneity we fitted a random effects (frailty) Cox model.

Analyses were performed using SPSS (SPSS Inc. Released 2009. PASW Statistics for Windows, Version 18.0. Chicago: SPSS Inc.), and IDE software RStudio (version 3.4.1 of 2017-06-30) for the R (version 2.1) using the packages “timeROC” and “survival”.



## Results

### Clinical and Features and Liver Stiffness

Baseline characteristics of the 1039 patients with NAFLD and cACLD are shown in Table 1. The diagnosis of NAFLD was supported by histology in 550 cases (52.9%), and 7.2% of the population had Child Pugh A6 score.

Baseline median LSM value was 17.6 KPa. LSM was obtained by using M probe in 776 patients and XL probe in 263 patients; as expected mean BMI ( $34.4\pm 6.5$  vs  $31.9\pm 5.8$ ;  $p<0.001$ ) as well as the prevalence of obesity (75.2% vs 60.2%;  $p<0.001$ ) were significantly higher in patients with LSM by XL probe compared to those with LSM by M probe.

In a sub-group of 533 patients LSM within 1 year from the last follow-up and obtained by using the same probe used at baseline was available. These patients were older and had higher length of follow-up compared to those without LSM available at follow-up (Supplemental Table 1). Median delay between baseline and follow-up LSM was 37 months. In this group of patients, 53.3% experienced an improvement in follow-up LSM ( $<20\%$  from baseline), 27.2% had stable values, and 19.5% had an impairment  $>20\%$  in LSM values from baseline. Notably, among these three classes of patients, the presence of diabetes at baseline significantly predicted follow-up changes in LSM (56.8 %, 68.2% and 71.1%, respectively;  $p=0.01$ ).

### Liver-related and Extrahepatic Outcomes

Absolute numbers and the actuarial incidence rates for hepatic and extra-hepatic events are reported in Supplemental Table 2.

### **Prediction of Liver Decompensation by LSM**

Independent variables predicting liver decompensation by Cox multivariate analysis included: age (HR 1.06, 95%CI 1.02-1.09,  $p=0.001$ ), presence of Child Pugh A6 (HR 3.04, 95%CI 1.69-5.44;  $p<0.001$ ), platelets (HR 0.98, 95%CI 0.97-0.98,  $p<0.001$ ) and baseline LSM (HR 1.03, 95%CI 1.02-1.04,  $p<0.001$ ) (Table 2). When including in the model PLT  $<150 \times 10^3/\text{mmc}$  as categorical variable instead of PLT as a continuous variable, similar results were observed for LSM and PLT  $<150 \times 10^3/\text{mmc}$  remained significant associated with liver decompensation (HR 7.83, 95%CI 2.51-21.3;  $p<0.001$ ). The time dependent ROC of baseline LSM in predicting liver decompensation was 0.76, 95% CI 0.68-0.83. The threshold of 21 KPa indicating clinically significant portal hypertension (CSPH) [13] was confirmed independently associated with higher occurrence of liver decompensation (HR 3.71, 95%CI 1.89-6.78;  $p<0.001$ ) (Figure 1).

In patients with LSM available at follow-up,  $\Delta$ -LSM (HR 1.56, 95%CI 1.05-2.51,  $p=0.04$ ) (Figure 2A), together with baseline LSM (HR 1.03, 95%CI 1.00-1.05,  $p=0.01$ ), significantly predicted the occurrence of liver decompensation (Table 2). Notably, the model including  $\Delta$ -LSM better predicted decompensation than the model without (H C-Index 0.86 vs 0.83, respectively;  $p=0.03$ ). Figure 3A showed the crude rate of liver decompensation at the end of follow-up among delta LSM risk classes. When assessing the risk for liver decompensation in patients with or without CSPH by LSM, we found that delta LSM significantly predicted liver decompensation in patients without (HR 3.85, 95%CI 1.38-9.5,  $p=0.003$ ) (Figure 4A and 4B), but not in those with CSPH (HR 1.45, 95%CI 0.93-2.21,

$p=0.07$ ). Moreover, in patients without baseline CSPH (LSM $<21$ kPa), the rate of liver decompensation occurrence was 6.5% in those who reached at follow-up a LSM value suggestive of CSPH, and 2.3% in those where LSM did not reach this threshold ( $p=0.07$ ).

### **Monitoring LSM do predict HCC occurrence**

Female gender (HR 0.30, 95%CI 0.13-0.69;  $p=0.005$ ), age (HR 1.06, 95%CI 1.01-1.09,  $p=0.007$ ), and baseline LSM (HR 1.03, 95%CI 1.00-1.04,  $p=0.003$ ) were independent variables by Cox-regression associated with the development of HCC (Table 2). When including in the model PLT  $<150 \times 10^3$ /mmc as categorical variable instead of PLT as a continuous variable, similar results were observed for LSM and PLT  $<150 \times 10^3$ /mmc was confirmed not significantly associated with HCC (HR 0.99, 95%CI 0.35-2.72;  $p=0.95$ ). The time dependent AUROC of baseline LSM in predicting HCC was clinically not acceptable (AUROC 0.66, 95%CI 0.49-0.83).

In patients with LSM available at follow-up,  $\Delta$ -LSM (HR 1.72, 95%CI 1.01-3.02,  $p=0.04$ ) (Figure 2B), but not baseline LSM (HR 1.02, 95%CI 0.98-1.05,  $p=0.27$ ) significantly predicted the occurrence of HCC (Table 2). Notably, the model including  $\Delta$ -LSM better predicted decompensation than the model without (H C-Index 0.84 vs 0.79, respectively;  $p=0.002$ ). Figure 3B shows the crude rate of HCC at the end of follow-up among delta LSM risk classes.

### **LSM does not predict extra-hepatic events occurrence**

Baseline LSM (HR 1.01, 95%CI 0.99-1.03,  $p=0.15$ ) and  $\Delta$ -LSM (HR 1.42, 95%CI 0.78-2.59,  $p=0.24$ ) were not associated with occurrence of cardiovascular events at univariate Cox regression analysis.

Baseline LSM was associated with occurrence of extra-hepatic neoplasm (HR 1.02, 95%CI 1.00-1.04,  $p=0.03$ ) in the univariate analysis but not at multivariate Cox regression analysis (HR 1.02, 95%CI 0.99-1.04,  $p=0.12$ ).  $\Delta$ -LSM was also not associated with the development of extrahepatic cancers (HR 0.78, 95%CI 0.42-1.45,  $p=0.44$ ) (Table 3).

### **$\Delta$ -LSM predicted overall and liver-related mortality**

Baseline LSM was not associated with overall mortality (HR 1.01, 95%CI 0.99-1.03,  $p=0.18$ ) (Table 2). In patients with LSM available at follow-up,  $\Delta$ -LSM (HR 1.73, 95%CI 1.11-2.69,  $p=0.01$ ) (Figure 2C) and Child-Pugh A6 vs Child-Pugh A5 (HR 4.09, 95%CI 1.01-16.4,  $p=0.04$ ), but not baseline LSM (HR 1.01, 95%CI 0.97-1.04,  $p=0.46$ ) were independently associated with overall mortality (Table 2). Figure 3C showed the crude rate of overall death among delta LSM risk classes.

Age (HR 1.06, 95%CI 1.02-1.11,  $p=0.005$ ), platelets (HR 0.99, 95%CI 0.98-0.99,  $p=0.01$ ) and baseline LSM (HR 1.02, 95%CI 1.00-1.03,  $p=0.005$ ) (time dependent ROC 0.76, 95% CI 0.60-0.91) were significant risk factors for liver-related death (Table 2). In patients with available delta LSM: age (HR 1.06, 95%CI 1.00-1.16,  $p=0.02$ ) and  $\Delta$ -LSM (HR 1.96, 95%CI 1.10-3.38,  $p=0.02$ ) (Figure 2D), but not baseline LSM (HR 1.02, 95%CI 0.98-1.06,  $p=0.18$ ) were independent variables predicting liver-related death (Table 2). Notably, the model including  $\Delta$ -LSM better predicted liver-related death than the model without (H C-Index 0.80 vs 0.77, respectively;  $p=0.03$ ). Figure 3D shows the crude rate of liver-related death among delta LSM risk classes.

Finally, nor baseline LSM (HR 1.00, 95%C.I. 0.97-1.03,  $p=0.75$ ) neither  $\Delta$ -LSM (HR 1.28, 95%C.I. 0.59-2.75,  $p=0.52$ ) were associated with extrahepatic death at univariate Cox regression analysis.

## Discussion

In the current study carried out in a large multicenter cohort of individuals with NAFLD and cACLD, and prospectively followed for a median time of 3 years, we found that baseline LSM accurately predicts liver decompensation and liver-related death, while changes overtime in LSM –delta LSM- can further stratify the risk of development of liver-related complications.

In our study, liver-related events were the most frequently observed complications (6.8% liver decompensation, 3.4% HCC), followed by cardiovascular events (3.4%) and extrahepatic cancers (2.4%). Moreover, we observed an overall death rate of 5.4%, mostly due to liver-related causes (3.2%). Long-term studies investigating the natural history of patients with biopsy-proven NAFLD reported cardiovascular events and extra-hepatic cancers as the two most frequent causes of death, even if the observed higher increase in the relative risk of death was showed for liver-related causes [16,17]. The occurrence rates of hepatic and extrahepatic outcomes that we reported differ with respect to other studies [16,17], perhaps due to the selection of a population with cACLD, already committed for a higher risk of liver-related complications.

Baseline LSM values accurately predicted the occurrence of liver decompensation. This result was maintained after adjusting for the severity of liver disease (Child-Pugh A5 versus A6) and for surrogate markers of portal hypertension (platelet count). Notably, we found that when using the LSM threshold of 21 KPa, validated as indicating a high risk for CSPH [13], also in a setting of patients at risk for decompensation because of with cACLD, we identified two different populations, one at low (2%) and another at high (14%) risk of hepatic decompensation. Our study agrees with recent evidence that higher baseline LSM values can predict the development

of liver-related events in NAFLD [18]. However this last study included a smaller cohort of patients with NAFLD and advanced liver disease, did not consider separately liver decompensation and HCC, and did not explore the clinical utility of LSM in the at high risk setting of patients with severe fibrosis/compensated cirrhosis [19]. Another relevant finding of our study is that delta LSM can further stratify the risk for liver decompensation. We demonstrated a progressive increase in the probability of hepatic decompensation from 3.8% in patients who improved LSM of at least 20%, to 6.2% in stable kPa -20% to 20%, and further to 14.4% in those who impaired LSM >20% from baseline. Notably, when stratifying patients according to the risk of CSPH, we showed that while in patients at high CSPH risk, the delta LSM did not longer predict hepatic decompensation, its predictability was maintained in patients at low risk of CSPH at baseline, indeed, LSM improvement was associated with no hepatic decompensation, while the risk progressively increased to 3.2% in stable stiffness, and further to 10% when LSM impaired.

Baseline LSM values were independently associated with the occurrence of HCC, even if the overall accuracy was not clinically acceptable. Consistent with our results, a recent study in NAFLD patients at any stage of liver fibrosis showed a significant link between HCC risk and LSM values, but the authors cannot find accurate specific cut-offs to predict HCC occurrence [18].  $\Delta$ -LSM but not baseline LSM, showed an independent association with the risk of developing HCC: from 2.4% in improvement to 3.4% in stable and further to 6.7% when impaired stiffness.

After adjusting for confounders, we found an independent association between baseline LSM and liver-related but not overall mortality. The good prediction ability of baseline LSM for liver-related mortality was also demonstrated in two independent studies focusing on patients with clinical diagnosis of NAFLD at any stage of liver fibrosis [19,20]. Regarding the association between overall

mortality and baseline LSM, some study reported a lower diagnostic performance of baseline LSM respect to the prediction of liver-related mortality [19], while some other study showed a good performance also for predicting overall mortality [18]. Differences in the baseline prevalence of liver disease severity and, consequently in the incidence of hepatic and extrahepatic events leading to mortality, can explain the observed differences among studies. Notably, when in our cohort we considered delta LSM, we found that it can significantly stratify the risk of both overall and hepatic death, suggesting that impairment in liver disease severity can also increase the risk for extra-hepatic mortality as also suggested in a recent meta-analysis [6].

We observed that 53% of patients with paired LSM had LSM improvement defined as LSM reduction  $>20\%$  from baseline, this percentage being higher than that reported in literature for at least 1 stage fibrosis regression in patients with paired liver biopsies [21]. However it is well known in literature that LSM in NASH is not only expression of hepatic fibrosis but it is also directly associated with ALT levels –as expression of liver inflammation- and BMI [22]. Consistently, the reduction of at least 20% that we observed in about half of NASH patients with paired LSM can be considered as a surrogate of improvement in liver damage (fibrosis and/or inflammation) and/or in its risk factors like obesity. Unfortunately, this is only a plausible hypothesis because data on ALT and BMI at follow-up were not available.

From a clinical point of view our study suggests that in a setting of patients with NAFLD at high risk of hepatic complications because of cACLD, a dynamic and integrated evaluation of baseline LSM together with delta LSM can help in stratifying the risk of liver decompensation, while delta LSM alone, not baseline, could better stratify the risk of HCC occurrence and of both hepatic and extra-hepatic death (Supplemental Figure 1). We can hypothesize that LSM impairment overtime can be expression of an impairment in liver

disease severity in terms of fibrosis, inflammation, steatosis and portal hypertension [10,22,23]. Notably, we found that the presence of diabetes at baseline indicates a higher risk of delta LSM impairment. This data agree with available literature identifying diabetes as a risk factor for liver disease progression and liver-related complications [24-26].

In our study we did not find any significant independent association between neither baseline nor delta LSM and occurrence of cardiovascular events and extra-hepatic cancers. Our results agree with data reported in a cohort of NAFLD patients at any stage of liver damage, where baseline LSM was not associated with extra-hepatic cancers while showing a statistically significant association but not clinically acceptable accuracy for cardiovascular event development [18].

The main limitation of this study lies in the potentially limited external validity of the results for different populations and settings. Our study included a large cohort of patients with NAFLD and advanced liver fibrosis followed at tertiary care centers. Another relevant limitation is the retrospective design of the study, and the not standardized protocol of LSM follow-up potentially leading to a selection bias. The lack of data about follow-up clinical variables including biochemical tests like ALT-expression of liver inflammation-and BMI could further limit the interpretation of our results. In particular, weight loss leading to BMI reduction is known to be associated with NASH resolution and fibrosis improvement in NAFLD patients [27], and ALT normalization has been identified as a predictor of histological improvement in NASH [28]; consistently the lack of data about the effect of ALT and BMI changes on liver-related outcomes can limit the strength of our results about LSM changes and prognosis in NAFLD population. In fact, delta LSM could be expression of factors also influencing the natural history of liver disease such as weight changes, transaminases fluctuations, or reflecting progression of liver disease such as changes in platelet count and in liver function indexes. Finally, hidden alcohol intake at



baseline and during follow-up, and lack of data about baseline and follow-up use of non-selective betablockers, could further affect the observed results.

In conclusion, this study conducted in a multicenter cohort of patients with NAFLD and cACLD showed that an integrated assessment of baseline and/or delta LSM can help in stratifying the risk of development of liver-related complications and of both hepatic and overall mortality. These data, if further validated, could help personalize prognosis and follow-up in NAFLD with cACLD.

## Legends

**Figure 1. Occurrence of liver decompensation in the entire cohort of NAFLD patients with cACLD according to LSM value of 21 KPa indicating a high risk of CSPH. p value by log-rank.**

**Figure 2. Delta LSM risk classes and occurrence of liver-related events and death in the entire cohort of NAFLD patients with cACLD. (A) Liver Decompensation; (B) Hepatocellular carcinoma; (C) Overall death; (D) Liver-related death. p value by log-rank.**

**Figure 3. Crude rate of liver-related events and death at the end of follow-up according to delta LSM risk classes in the entire cohort of NAFLD patients with cACLD. (A) Liver Decompensation; (B) Hepatocellular carcinoma; (C) Overall death; (D) Liver-related death. p value by log-rank.**

**Figure 4. Occurrence (A) and crude rate (B) of liver decompensation in the sub-group of patients with NAFLD and without CSPH by LSM (LSM <21 KPa).**

**Supplemental Figure 1. Proposed Algorithm to stratify the risk of complications in patients with cACLD by using baseline and delta LSM.**

**References**

1. Younossi ZM et al. Global Epidemiology of Non-Alcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence and Outcomes. *Hepatology*. 2016 Jul;64(1):73-84.
2. Younossi ZM et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. *J Hepatol*. 2019 Oct;71(4):793-801.
3. Dyson J et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. *J Hepatol*. 2014 Jan;60(1):110-7.
4. Wong RJ et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. *Gastroenterology*. 2015 Mar;148(3):547-55.
5. Adams LA et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. *Gut*. 2017 Jun;66(6):1138-1153.
6. Dulai PS . Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. *Hepatology*. 2017 May;65(5):1551-1565.

7. Grimaudo S et al. Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease. *Clin Gastroenterol Hepatol*. 2019 Aug 13. pii: S1542-3565(19)30886-9.
8. Vilar-Gomez E et al. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. *Gastroenterology*. 2018 Aug;155(2):443-457.e17.
9. Xiao G et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. *Hepatology*. 2017 Nov;66(5):1486-1501.
10. Petta S et al. Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. *J Hepatol*. 2018 Oct;69(4):878-885.
11. Pons M et al. Non-invasive prediction of liver related events in HCV compensated advanced chronic liver disease patients after oral antivirals. *J Hepatol*. 2019 Oct 17. pii: S0168-8278(19)30606-3. doi:10.1016/j.jhep.2019.10.005.
12. de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. *J Hepatol*. 2015 Sep;63(3):743-52.
13. Cillo U et al; I-BELT (Italian Board of Experts in the Field of Liver Transplantation). A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a "Blended Principle Model". *Am J Transplant*. 2015 Oct;15(10):2552-61.
14. Boursier J et al; Multicentric Group from ANRS/HC/EP23 FIBROSTAR Studies. Determination of reliability criteria for liver stiffness evaluation by transient elastography. *Hepatology*. 2013;57:1182-91.

15. Estes C et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. *J Hepatol.* 2018 Oct;69(4):896-904.
16. Ekstedt M et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology.* 2015 May;61(5):1547-54.
17. Angulo P et al. Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology.* 2015 Apr 29. pii: S0016-5085(15)00599-5.
18. Shili-Masmoudi S et al. Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. *Liver Int.* 2019 Nov 20. doi: 10.1111/liv.14301.
19. Munteanu M et al; FibroFrance Group. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. *Aliment Pharmacol Ther.* 2018 Nov;48(10):1117-1127.
20. Boursier J et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. *J Hepatol.* 2016 Sep;65(3):570-8.
21. Siddiqui MS et al; NASH Clinical Research Network. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. *Clin Gastroenterol Hepatol.* 2019 Aug;17(9):1877-1885.e5.
22. Petta S et al. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. *Am J Gastroenterol.* 2019 Jun;114(6):916-928.

23. Petta S et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. *Hepatology*. 2017 Apr;65(4):1145-1155.
24. Pelusi S et al. Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. *PLoS One*. 2016 Sep 20;11(9):e0163069.
25. Huang YW et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study. *Hepatology*. 2014 Sep;60(3):807-14.
26. Yang JD et al. Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. *Hepatology*. 2019 Jul 15. doi: 10.1002/hep.30858.
27. Vilar-Gomez E et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. *Gastroenterology*. 2015 Aug;149(2):367-78.e5.
28. Vilar-Gomez E et al. Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH. *Liver Int*. 2017 Dec;37(12):1887-1896.

**Table 1. Baseline Demographic, Metabolic, Laboratory and Instrumental Features of patients with NAFLD and cACLD.**

	<b>NAFLD with cACLD N=1039</b>
<b>Mean Age – years</b>	60.3 ± 10.7
<b>Male Gender</b>	56.3 %
<b>Mean BMI – Kg/m<sup>2</sup></b>	32.4 ± 6.1
<b>Obesity -BMI≥30Kg/m<sup>2</sup></b>	66.3%
<b>ALT – IU/L</b>	62.8 ± 50.3
<b>PLT – 10<sup>3</sup>/mmc</b>	186.6 ± 74.3
<b>Total Bilirubin – mg/dL</b>	0.7±0.4
<b>INR</b>	1.0±0.2
<b>Albumin – g/L</b>	4.2 ± 0.4
<b>Blood Glucose – mg/dL</b>	128.0 ± 80.4
<b>Total Cholesterol – mg/dL</b>	171.4 ± 53.5
<b>Triglycerides – mg/dL</b>	150.5 ± 99.4
<b>Type 2 Diabetes</b>	60.8 %
<b>Arterial Hypertension</b>	68.2%
<b>LSM– Kpa (Median and 1st/3rd quartiles)</b>	17.6 (13.1/26.1)
<b>Child A5/A6</b>	92.8%/7.2%
<b>Time of follow-up – months (Median and 1st/3rd quartiles)</b>	35 (19/63)

Abbreviations: BMI, body mass index; PLT, platelet; ALT, alaninoaminotransferase; LSM, liver stiffness measurement. Data are given as mean ± standard deviation, or as percentage of cases (%).

<b>Group</b>	<b>Variable</b>	<b>Adjusted Model HR (95% C.I.) p value</b>	<b>Adjusted Model HR (95% C.I.) p value</b>
--------------	-----------------	---	---

Journal Pre-proof

**Table 2. Cox regression analysis of factors associated with liver events and liver-related death in the entire cohort of NAFLD and cACLD.**

		<b>Entire Cohort (N=1039)</b>	<b>Cohort with Availability of Follow-up LSM (N=533)</b>
<b>Liver Decompensation</b>	<b>Age – years</b>	1.06 (1.02-1.09) 0.001	1.06 (1.00-1.11) 0.02
	<b>Child Pugh A6</b>	3.04 (1.69-5.44) <0.001	1.63 (0.49-5.28) 0.42
	<b>PLT - 10<sup>9</sup>/mmc</b>	0.98 (0.97-0.98) <0.001	0.98 (0.97-0.98) <0.001
	<b>Baseline LSM -KPa</b>	1.03 (1.02-1.04) <0.001	1.03 (1.00-1.05) 0.01
	<b>Delta LSM -KPa</b>	-	1.56 (1.05-2.51) 0.04
		<b>Entire Cohort (N=1039)</b>	<b>Cohort with Availability of Follow-up LSM (N=533)</b>
<b>Hepatocellular Carcinoma</b>	<b>Female gender</b>	0.30 (0.13-0.69) 0.005	0.28 (0.08-0.85) 0.02
	<b>Age – years</b>	1.06 (1.01-1.09) 0.007	1.04 (0.98-1.10) 0.13
	<b>PLT- 10<sup>9</sup>/mmc</b>	1.00 (0.99-1.00) 0.25	1.00 (0.99-1.00) 0.73
	<b>Child Pugh A6</b>	0.80 (0.25-2.49) 0.71	3.25 (0.80-13.1) 0.09
	<b>Baseline LSM -KPa</b>	1.03 (1.00-1.04) 0.003	1.02 (0.98-1.05) 0.27
	<b>Delta LSM -KPa</b>	-	1.72 (1.01-3.02) 0.04
			<b>Entire Cohort (N=1039)</b>
<b>Cardiovascular Event</b>	<b>Female gender</b>	0.46 (0.21-0.96) 0.04	0.18 (0.03-0.78) 0.02
	<b>Age – years</b>	1.03 (0.99-1.07) 0.08	1.06 (0.99-1.13) 0.07
	<b>Arterial Hypertension</b>	2.16 (0.81-5.72) 0.12	3.03 (0.67-13.6) 0.15
		<b>Entire Cohort (N=1039)</b>	<b>Cohort with Availability of Follow-up LSM (N=533)</b>
<b>Extra-hepatic Cancer</b>	<b>Age – years</b>	1.04 (0.99-1.08) 0.06	1.04(0.98-1.09) 0.19
	<b>Child Pugh A6</b>	1.78 (0.51-6.07) 0.36	1.12 (0.13-9.46) 0.92
	<b>Baseline LSM -KPa</b>	1.02 (0.99-1.04) 0.12	1.01 (0.97-1.04) 0.756
		<b>Entire Cohort (N=1039)</b>	<b>Cohort with Availability of Follow-up LSM (N=533)</b>
<b>Overall Death</b>	<b>Female gender</b>	0.62 (0.33-1.14) 0.13	0.60 (0.27-1.33) 0.21
	<b>Age – years</b>	1.04 (1.01-1.08) 0.01	1.04 (0.99-1.08) 0.09
	<b>BMI –Kg/m<sup>2</sup></b>	0.91 (0.84-0.97) 0.006	0.93 (0.85-1.02) 0.12
	<b>Child Pugh A6</b>	4.22 (1.83-9.71) <0.001	4.09 (1.01-16.4) 0.04
	<b>PLT - 10<sup>9</sup>/mmc</b>	1.00 (0.99-1.00) 0.21	1.00 (0.99-1.00) 0.78
	<b>Baseline LSM -KPa</b>	1.01 (0.99-1.03) 0.18	1.01 (0.97-1.04) 0.46
	<b>Delta LSM -KPa</b>	-	1.73 (1.11-2.69) 0.01
		<b>Entire Cohort (N=1039)</b>	<b>Cohort with Availability of Follow-up LSM (N=533)</b>
<b>Liver-related Death</b>	<b>Age – years</b>	1.06 (1.02-1.11) 0.005	1.06 (1.00-1.16) 0.02
	<b>Child Pugh A6</b>	1.71 (0.60-4.13) 0.36	2.12 (0.31-11.5) 0.49
	<b>PLT - 10<sup>9</sup>/mmc</b>	0.99 (0.98-0.99) 0.01	0.99 (0.98-1.00) 0.34
	<b>Baseline LSM –Kpa</b>	1.02 (1.00-1.03) 0.005	1.02 (0.98-1.06) 0.18



	<b>Delta LSM -Kpa</b>	-	1.96 (1.10-3.38) 0.02
--	-----------------------	---	-----------------------

Journal Pre-proof




Figure 1




Figure 2A




Figure 2B




Figure 2C




Figure 2D




Figure 3A




Figure 3B






Figure 3C




Figure 3D




Figure 4A




Figure 4B

## What You Need to Know

Background: It is not clear whether, in patients with nonalcoholic fatty liver disease (NAFLD) and compensated advanced chronic liver disease, baseline liver stiffness measurements (LSMs) or their changes can be used to identify patients at risk for liver-related and extrahepatic events.

Findings: In patients with NAFLD and compensated advanced chronic liver disease, baseline LSM and change in LSM are associated with risk of liver-related events and mortality.

Implications for patient care: LSMs should be made at multiple timepoints in patients with NAFLD and compensated cirrhosis to monitor disease progression.